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A B s T r A C T
Alpha-1 antitrypsin (A1AT) is an acute-phase protein that 
is produced in liver cells. A1AT deficiency is a hereditary 
disease which is defined by the hepatic production of 
an abnormal protein that can not be released into the 
plasma. This leads to deficiency of plasma A1AT and 
subsequently to an impaired protection against proteases, 
resulting in pulmonary disease. Accumulation of the 
abnormal protein in hepatocytes can lead to liver damage. 
serum level measurement, phenotyping and liver biopsy 
can be used for establishing the diagnosis. 
Homozygous A1AT deficiency can cause neonatal 
hepatitis; in adults end-stage liver disease, cirrhosis and 
hepatocellular carcinoma can develop. There are strong 
arguments to consider heterozygous A1AT deficiency as 
an important co-factor in the aetiology of chronic liver 
disease. studies have shown that A1AT heterozygosity can 
be considered a modifier for hepatitis C virus, end-stage 
liver disease, cirrhosis and hepatocellular carcinoma. The 
accumulation of A1AT in the hepatocytes occurs more 
profoundly in a diseased liver, and as a consequence it 
affects the natural course of the liver disease. Therapeutic 
options include augmentation therapy (infusion of 
purified human plasma A1AT) in pulmonary disease; in 
end-stage liver disease liver transplantation is an option. 
for the future, other interventions such as gene therapy or 
strategies to inhibit polymerisation are promising.
K E Y W o r d s
Alpha-1-antitrypsin deficiency, hepatocellular carcinoma, 
heterozygosity, liver disease
i N T r o d U C T i o N
Alpha-1 antitrypsin (A1AT) is an acute-phase protein that 
is produced in liver cells. It is released into the plasma in 
response to an inflammatory stimulus. A1AT deficiency is a 
hereditary disease that is defined by the hepatic production 
of an abnormal protein that can not completely be released 
into the plasma. This leads to deficiency of plasma A1AT 
and subsequently to an impaired protection of the lungs 
against proteases. This results in pulmonary emphysema; 
hepatic accumulation of the abnormal protein can lead to 
chronic liver disease. This review gives an update of the 
present knowledge on partial A1AT deficiency in relation 
to various liver diseases.
 
G E N E T i C s  A N d  ( P A T H o ) P H Y s i o l o G Y
The A1AT molecule is a serum glycoprotein acting as an 
acute-phase protein. It is released during inflammatory 
processes from the hepatocyte, which results in increased 
plasma concentrations. The major physiological function 
© 2007 Van Zuiden Communications B.V. All rights reserved.
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of this protein is the inhibition of destructive neutrophil 
elastase, thus protecting against pulmonary damage.1
The A1AT protein is encoded by the protease inhibitor 
(Pi) locus located on chromosome 14q32.1. The Pi locus is 
highly polymorphic, resulting in different A1AT isotypes 
that can be detected by electrophoresis. 
The most common allele is the M allele that results in a 
functionally normal protein with normal serum A1AT levels. 
The normal A1AT protein has a tertiary structure based on a 
large central β-sheet, surrounded by two other sheets and a 
reactive centre loop. The reactive centre loop can move in and 
out of the large β-sheet. At higher temperatures polymerisation 
can occur between molecules due to insertion of the loop of 
one molecule into the large β-sheet of the other.
The point mutation, found in the Z variant, destabilises the 
loop-sheet polymerisation of the A1AT molecule, resulting 
in chains of polymers that are retained in the hepatocytes. 
These polymers accumulate in the endoplasmatic reticulum 
of the hepatocytes and may be recognised as PAS(+) 
inclusion bodies (figure 1). Only 15% of the Z variant of A1AT 
can be secreted into the plasma, the other 85% accumulates 
in the liver. In Pi ZZ homozygous subjects, this results in 
a severe deficiency of serum A1AT and in accumulation of 
the abnormal protein in the endoplasmatic reticulum of the 
hepatocyte, which can lead to chronic liver disease.
The S variant of the A1AT molecule has less effect on 
the loop-sheet polymerisation. Formation of S polymers 
is slower, resulting in less retention of protein in the 
hepatocytes compared with the Z variant. There is a mild 
reduction in serum A1AT levels. When an S and a Z variant 
are coinherited, the two interact with the formation of 
polymers within the hepatocytes; this can lead to reduction 
in the serum A1AT level, inclusion of the polymers, 
accumulation and subsequently development of cirrhosis.
Less frequently found variants are null alleles resulting in 
undetectable A1AT levels due to intracellular degradation 
or intracellular accumulation of the protein; this is usually 
associated with severe pulmonary disease, but not with 
liver disease (table 1).2-7 
A1AT deficiency is characterised by an imbalance between 
the protease neutrophil elastase and the protease inhibitor 
A1AT. It has been suggested that neutrophil elastase 
might promote the development of cancer.8 The exact 
carcinogenic mechanism or sequence is not known.
In a recent paper, the hypothesis was given that in A1AT 
deficiency, the hepatocytes in which A1AT is accumulated 
are inhibited in their growth, but they do express 
regenerative signals. Relatively normal cells, without A1AT 
deposits, are thereby stimulated and this chronic stimulation 
of regeneration may lead to the formation of neoplasmata.9
d i A G N o s T i C  A s P E C T s
To establish the diagnosis, various methods are available. 
The A1AT serum level can be determined by clinical 
chemistry. In homozygous A1AT deficiency the level is 
very low. However, in the heterozygous variant the A1AT 
level can be within the normal range, especially during 
an acute-phase reaction. Therefore, electrophoresis should 
be performed in any case of suspected A1AT deficiency 
in order to determine the phenotype. Liver biopsy is the 
Table 1. Characteristics of the different A1AT alleles
Allele Mutation Cellular defect Enzymatic 
activity
M - - Normal
S Glu264Val Intracellular 
degradation
Intermediate
Z Glu342Lys Intracellular 
accumulation
Low
Null Different 
mutations
Most mutations 
no mRNA
Null
A
B
C
figure 1. Liver biopsy: cirrhosis due to alcohol abuse and 
heterozygosity for α1 antitrypsin (A1AT) deficiency33
A. HE staining, 20x: micro nodular liver cirrhosis. 
B. d-PAs staining, 40x: diastase resistant, Periodic-schiff-Acid 
positive globuli, matching with A1AT accumulation. 
C. A1AT antibodies, 40x: confirmation of A1AT accumulation.
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gold standard for establishing A1AT accumulation and 
PAS-positive, diastase-resistant inclusions can be found. 
A specific immunohistochemical staining can confirm the 
diagnosis. It is also possible to determine the phenotype 
on paraffin-embedded liver slides.
E P i d E M i o l o G Y
Despite the fact that A1AT deficiency is a common disorder, 
it is poorly recognised in clinical practice. There are 
probably two main reasons for this; first in patients with 
liver disease, the diagnosis is not always considered and 
second not all subjects with a deficient phenotype develop 
liver disease, i.e. the penetrance is low.10 
Given this well-known underdiagnosis, the real prevalence 
of A1AT deficiency has mainly been determined by 
epidemiological methods, either using a control cohort from 
an epidemiological study, or through neonatal screening. The 
Z allele is especially prevalent in Northern Europe, while the 
S allele is prevalent in Southern Europe (table 2).11-15
C l i N i C A l  A s P E C T s
Pulmonary disease
A1AT deficiency is associated with less inhibition 
of elastase resulting in pulmonary disease. A1AT 
homozygosity (Pi ZZ) results in a pulmonary 
phenotype with early onset of emphysema, asthma and 
bronchiectasia. A1AT deficiency results in panacinar 
pathology and disproportionate emphysematous 
involvement of the lung bases. Tobacco smoking 
is the most important additional risk factor for the 
development of pulmonary disease. Also subjects with 
the Pi MZ phenotype have an increased risk of developing 
pulmonary disease.7
Neonatal/paediatric liver disease
A1AT deficiency is the most common genetic cause of liver 
disease in early childhood. The most common presentation is 
by prolonged jaundice. The stools generally contain no yellow 
or green pigment, indicating cholestasis and mimicking 
biliary atresia. All patients have hepatomegaly and about 50% 
also have splenomegaly. Approximately 5% of the patients 
present with an increased bleeding tendency. This is due 
to vitamin K deficiency caused by the cholestasis-induced 
malabsorption. Less commonly children present later in 
childhood with hepatosplenomegaly or with cirrhosis.16-19
In Sweden, between 1972 and 1974, 200,000 neonates 
were screened for A1AT deficiency: 120 Pi ZZ (0.06%), 
2 Pi Z-, 54 Pi SZ and 1 Pi S- children were found. Only 14 
of the Pi ZZ children had prolonged jaundice, nine of those 
had severe liver disease. All infants appeared healthy at six 
months of age. Infants with a Pi SZ phenotype had no signs 
of liver disease.
At the age of 16 years, elevated liver enzymes were 
found in 17% of Pi ZZ adolescents and in 8% of Pi SZ 
adolescents. The adults with liver disease in infancy 
were clinically healthy. At the age of 26 years, the Pi 
ZZ subjects were compared with Pi MM individuals. 
The Pi ZZ subjects had normal lung function; 4 to 9% 
of them had mild liver test abnormalities.11,20,21 In the 
Province of Bozen in Northern Italy, Pi phenotyping in 
umbilical cord blood was performed as a routine neonatal 
screening. About 5% of Pi SZ children were affected by 
liver involvement with elevated liver enzymes and 7% of 
833 Pi MZ heterozygotes had elevated liver enzymes in 
early childhood. At the age of 5 and 10 years, none had 
liver disease. The serum levels of A1AT were similar in the 
groups with and without liver test abnormalities; however 
these values had a wide range.22,23 
Although these studies suggest a good prognosis for neonatal 
cholestasis due to A1AT deficiency, other studies have 
described children who developed severe liver disease.16,19
Table 2. Epidemiology10-15
Country frequency Method Year
Pi ZZ Pi MZ Pi sZ
Sweden 0.06% - 0.03% Neonates, phenotyping when serum A1AT 
<40% 
1976
The Netherlands Z allele  
0.03%
- S allele  
0.04%
Neonates, phenotyping when A1AT/trans-
ferrine <1,2
1980
France 0.01% 2% 0.15% Control cohort epidemiological study 2003
Spain 0.01% - 0.2% Control cohort epidemiological study 2003
Italy 0.02% 2.4% 0.06% Control cohort epidemiological study 2003
Portugal 0.02% 2.3% 0.3% Control cohort epidemiological study 2003
Australia 0.02% 2.5% 0.12% Control cohort epidemiological study 2003
USA 0.02% 2.7% 0.09% Control cohort epidemiological study 2003
New Zealand 0.05% 4.3% 0.17% Control cohort epidemiological study 2003
Canada 0.02% 2.7% 0.11% Control cohort epidemiological study 2003
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liver disease in homozygous A1AT-deficient adults
Liver disease due to A1AT deficiency generally presents at 
adult age. One study reviewed adult patients with liver disease 
and A1AT deficiency; the mean age of the patients when 
liver disease became symptomatic was 58 years for the ZZ 
phenotype, 66 years for the SZ phenotype and 73 years for 
the MZ phenotype. At the time of diagnosis the liver disease 
was advanced, 42% of these patients died within two years.24
A review of autopsy data on 94 Pi ZZ homozygous A1AT 
deficient patients showed that cirrhotic patients survived 
longer compared with noncirrhotic patients. The noncirrhotic 
patients had more severe lung disease and died earlier.25 
A cohort of patients who are registered in the Alpha-1 
Foundation Registry (a USA foundation providing increased 
research and improved health for A1AT deficiency), and 
who had reported liver disease or jaundice (165 of the 2175 
participants in the registry) completed a questionnaire. Of 
these patients 71% were Pi ZZ and 18% were Pi MZ, the 
remainder did not know what their phenotype was. Mean 
age at diagnosis of liver disease was 31 years (range 0 to 
68 years), 30% had undergone liver transplant or were on 
the waiting list. Male gender and obesity were risk factors 
for advanced liver disease, while white race, Pi phenotype, 
infant jaundice, diabetes or hypercholesterolaemia were 
not.26 Although this survey is the largest cohort of A1AT 
deficiency and liver disease in the literature, the self-
selected cohort runs a risk of inclusion bias.
The natural history of the disease is not completely known. 
The risk of cirrhosis in adults is difficult to estimate because 
most available data are retrospective and derived from patients 
known to have A1AT-deficient lung disease or cirrhosis.27,28
Heterozygous A1AT deficiency and liver disease
Although the role of homozygous A1AT in liver disease 
is established, the association between heterozygous 
A1AT deficiency and chronic liver disease is still subject 
to ongoing investigation. Several studies, however, have 
shown an association between heterozygous A1AT 
deficiency and chronic liver disease.
In 1981 a study showed the association between Pi MZ and 
liver disease. About 1055 liver biopsies were screened for A1AT 
depositions in hepatocytes. A total of 34 patients with these 
inclusions were phenotyped; the prevalence of phenotype Pi 
MZ in the whole biopsy group was 2.4%. In liver cirrhosis, 
9% had a Pi MZ phenotype. A percentage of 21% Pi MZ was 
found in cryptogenic cirrhosis and in chronic active hepatitis, 
this was significantly increased compared with other causes 
of cirrhosis. The prognosis of the Pi MZ cirrhotic patients was 
poor, most patients died within one year.29 
More recently patients with end-stage liver disease, in 
work-up for liver transplantation, were investigated. Pi 
MZ was found in 7.3 to 8.2%, compared with 2.8% in the 
control population. A heterozygous phenotype was more 
prevalent in patients with hepatitis C, alcoholic liver disease, 
cryptogenic cirrhosis and hepatocellular carcinoma.30,31
In one study consecutive liver biopsies and autopsies were 
screened for Pi Z deposits. In the biopsy group 3.4% of cases 
were Pi MZ phenotyped, whereas in the autopsy group this 
was 1.8%. In biopsies from older people heterozygous for 
A1AT, more fibrosis and more Pi Z deposits were found; the 
liver involvement seems to be age-dependent. When there 
was another liver disease as well, the patients presented with 
more inflammation, more fibrosis and more Pi Z deposits 
than the biopsies without concomitant liver disease.32
We described three patients with alcoholic liver disease 
and a rapidly deteriorating clinical course, resulting in 
the patients’ death. All three patients were found to be 
heterozygous for A1AT.33
To summarise, these studies showed that various liver 
diseases influence the A1AT accumulation and that the 
A1AT accumulation influences the course of the liver 
disease. The risk of developing liver cirrhosis is increased 
in patients with heterozygous A1AT deficiency, also without 
coexisting liver disease. The exact impact and involvement 
of liver disease by heterozygous A1AT deficiency are 
unknown. Further research is needed to give these data. 
Heterozygous A1AT deficiency and coexisting hepatitis C 
virus infection
The role of A1AT deficiency in the severity and the course of 
liver disease in chronic hepatitis C virus (HCV) infection is 
not clear, despite the fact that several studies have analysed 
the association of HCV-induced liver disease and A1AT 
deficiency. 
In Austria, 1865 patients referred for the evaluation of 
chronic liver disease were analysed, 9% had a deficient 
phenotype. From these patients with cirrhosis, 62% were 
HCV positive, 33% had evidence of HBV infection, 41% 
abuse of alcohol and 12% had features of autoimmune 
liver disease. Out of 53 cirrhotic A1AT-deficient patients, 
only five had no coexisting liver disease. These authors 
concluded that the risk for chronic liver disease is increased 
in patients with the Pi Z gene, because they may have 
increased susceptibility to viral infection or additional 
factors, necessary to induce chronic liver disease.34
The same authors investigated the prognosis of patients with 
A1AT deficiency. Some 54 patients with A1AT deficiency 
had evidence of chronic liver disease, 78% showed positive 
viral markers (hepatitis B or hepatitis C); this was compared 
with 106 patients with A1AT deficiency without chronic 
liver disease, without signs of additional viral infection. 
Life expectancy in A1AT-deficient patients was significantly 
lower in patients with chronic liver disease in comparison 
with patients without chronic liver disease.35
Patients with end-stage liver disease, in work-up for 
liver transplantation, were also investigated. In the HCV 
patients Pi MZ was found in 10 to 13%, compared with 
2.8% in the control population. This suggests that an 
abnormal heterozygous phenotype is a co-factor in the 
development of chronic liver disease in HCV.30,31
Kok, et al. Alpha-1 antitrypsin deficiency as co-factor for chronic liver disease.
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In contrast, other studies showed no association between 
hepatitis C infection and A1AT deficiency.36-38
To conclude, the results of these studies are controversial. 
Some studies show a higher incidence of A1AT deficiency 
in HCV infection and an increased susceptibility to viral 
infections in A1AT deficiency and other studies do not. 
Different methods to determine the A1AT state were used. 
Further research on the influence of A1AT deficiency in 
the course of HCV infection and vice versa is necessary. 
Heterozygous A1AT deficiency and hepatocellular 
carcinoma
Established risk factors for hepatocellular carcinoma 
include chronic hepatitis B, HCV infection and alcoholic 
liver cirrhosis. Several studies have investigated the 
correlation between A1AT deficiency and hepatocellular 
carcinoma.39,40
In 1986 it was suggested for the first time that men 
with A1AT deficiency may be at risk for cirrhosis and 
hepatocellular carcinoma (HCC). Autopsy was performed 
in 16 adult patients with A1AT deficiency. In five out of 
these 16 patients, an HCC was found.41,42
In 317 HCC patients, Pi Z deposits were found in 6% 
compared with 1.8% in the control group. In heterozygous 
A1AT deficiency, HCC had also developed in noncirrhotic 
livers and was frequently characterised by cholangio-
cellular differentiation. In patients with A1AT deficiency 
bile duct lesions were frequently found. This might reflect 
a predisposition for the liver tissue for developing tumours 
with cholangiolar differentiation in A1AT deficiency.43,44 
In contrast to these studies, others did not show an 
association between A1AT deficiency and hepatocellular 
carcinoma, although carcinomas in noncirrhotic livers 
were Pi MZ associated. 45-48
To summarise, several studies have been performed to 
investigate the relation between A1AT deficiency and 
hepatocellular carcinoma. The outcomes are not uniform. 
In our opinion studies with large cohorts of patients with 
hepatocellular carcinoma are the most reliable; these 
studies did find an association. 
A1AT deficiency and associations with other diseases
A1AT deficiency is not only associated with liver and lung 
disease. Associations with panniculitis, nephrotic syndrome, 
intracranial aneurysm, hereditary haemochromatosis and 
celiac disease have been described.49-62
T H E r A P Y
Most therapeutic strategies in the treatment of A1AT 
deficiency are directed towards the pulmonary disease. 
Infusion of purified pooled human plasma A1AT is known 
as augmentation therapy. The goal of this treatment is 
to raise and maintain serum A1AT concentrations above 
the protective threshold. Data from different studies 
suggest that intravenous augmentation therapy has a 
positive biochemical and clinical effect. The therapy is 
expensive (US $ 28,075 to 65,973 per year).7 Different 
concepts have been studied to prevent the polymerisation 
and accumulation of the A1AT protein. New peptides 
that block the polymerisation of the Z protein have been 
developed.63,64 Gene therapy by injecting adeno-associated 
virus carrying the human A1AT gene is another promising 
concept.65 Liver transplantation is used in end-stage liver 
disease and results in acquisition of the donor phenotype, 
a rise in serum levels of A1AT and prevention of associated 
diseases.66
C o N C l U s i o N
Alpha-1 antitrypsin deficiency is an autosomal recessive 
disorder that can lead to chronic pulmonary disease and 
liver disease. The liver disease is caused by accumulation 
of an abnormal, polymerised protein. Deficient phenotypes 
are present worldwide. 
Homozygous A1AT deficiency in children can cause 
neonatal hepatitis. In adults homozygous patients are at 
risk for developing end-stage liver disease, cirrhosis and 
hepatocellular carcinoma. Heterozygous A1AT deficiency 
is probably an important co-factor in the aetiology of 
chronic liver disease, as several studies have shown 
associations with HCV, end-stage liver disease, cirrhosis 
and HCC. 
Low-threshold screening for A1AT deficiency should 
therefore be carried out. A1AT serum levels may be 
used, but phenotyping is crucial, as serum levels may 
not reflect true deficiencies (as inflammation serum 
levels can be falsely normal). Especially in cryptogenic 
chronic liver disease and liver disease that deteriorates 
faster than may be expected, A1AT deficiency may be of 
clinical significance as a (co)-factor. Clinical research is 
needed in A1AT-related liver disease to investigate the 
association between heterozygous A1AT deficiency and the 
presentation and course of liver diseases.67
We believe that the current data are insufficient to decide 
on the pros and cons of screening on hepatocellular 
carcinoma in A1AT deficiency. Therapeutic options in A1AT 
deficiency include augmentation therapy in pulmonary 
disease; in end-stage liver disease liver transplantation 
is an option. For the future, gene therapy or strategies to 
inhibit polymerisation are promising.
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